The Adulthood GH Deficiency Expert Working Group (EWG) was formed in 2023. In addition to testing and using the GloBE-Reg platform and stimulating the development of studies, the EWG will also develop a recommendation for a minimum dataset that should be collected in all adults with GH deficiency who may receive rhGH therapy. The EWG also has representation from industry and patient associations.
All EWGs have a Remit and a maximum duration of 2 years.
Current Activities
- Development of the minimum dataset for monitoring safety and effectiveness of rhGH in Adulthood GHD
- Adulthood GHD module launched August 2024
- Presentation on Adulthood GHD MDS at ECE 2024, Stockholm, May 2024
Members:
| Gudmundur Johannsson | Chair, Gothenburg, Sweden |
| Andrew Hoffman | Chair, Stanford, USA |
| Deno Andrews | Chicago, USA |
| Beverly MK Biller | Boston, USA |
| Cesar Boguszewski | Curitiba, Brazil |
| Lisette Cespedes | Pfizer |
| Anne Bro Bjørnelund | Ascendis |
| Peter Clayton | Manchester, UK |
| Maria Fleseriu | Portland, USA |
| Judith Gebaeur | Lübeck, Germany |
| Ken Ho | Sydney, Australia |
| Michael Højby | Novo Nordisk |
| Jens Otto Jørgensen | Aarhus, Denmark |
| Xiaoping Luo | Wuhan, China |
| Brad Miller | Minneapolis, USA |
| Sebastian Neggers | Rotterdam, Netherlands |
| Lars Sävendahl | Stockholm, Sweden |
| Katherina Schilbach | Munich, Germany |
| Aimee Shu | Ascendis |
| Christian Strasburger | Berlin, Germany |
| Yutaka Takahashi | Kobe, Japan |
| Diana Vitali | SOD Italia |
| Kevin CJ Yuen | Phoenix, USA |
| Markus Zabransky | Sandoz |
| Ching Chen | GloBE-Reg Project Management |
| Faisal Ahmed | GloBE-Reg Project Management |
Declarations of Interests Table
Members of the Adulthood GHD can access a private area here
Last Modified